Provided by Tiger Trade Technology Pte. Ltd.

Tscan Therapeutics, Inc.

0.3204
+0.00250.79%
Post-market: 0.32680.0064+2.00%18:27 EDT
Volume:873.12K
Turnover:276.05K
Market Cap:21.72M
PE:-0.36
High:0.3250
Open:0.3242
Low:0.3055
Close:0.3179
52wk High:2.57
52wk Low:0.3055
Shares:67.78M
Float Shares:57.82M
Volume Ratio:0.56
T/O Rate:1.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9000
EPS(LYR):-2.2805
ROE:-95.80%
ROA:-31.53%
PB:0.31
PE(LYR):-0.14

Loading ...

TScan Therapeutics Launches Executive Retention Incentive Program

TIPRANKS
·
Sep 11

TScan Rolls Out Retention Plan with $822,000 Cash Award for CEO Gavin MacBeath

Reuters
·
Sep 11

TScan Therapeutics, Inc. : H.c. Wainwright Cuts to Neutral from Buy

THOMSON REUTERS
·
Sep 08

TScan Therapeutics Cut to Hold from Buy by Needham

Dow Jones
·
Sep 03

TScan Therapeutics Inc : Needham Cuts to Hold from Buy

THOMSON REUTERS
·
Sep 03

U.S. Stocks on the MOVE-FuelCell, Gold Miners, NetApp

Reuters
·
Sep 03

TScan Therapeutics Inc : Wedbush Cuts to Neutral from Outperform; Cuts Target Price to $1 from $5

THOMSON REUTERS
·
Sep 02

TScan Therapeutics Restructures to Focus on Solid Tumors

TIPRANKS
·
Sep 02

TScan Therapeutics Falls After Pausing Cancer Trial

Reuters
·
Sep 02

TScan Therapeutics - Expects to Complete Strategic Reorganization by End of Q4 2026 - SEC Filing

THOMSON REUTERS
·
Sep 02

TScan Therapeutics - CEO Gavin Macbeath Assumes Principal Financial and Accounting Officer Duties as of Sept 2, 2026 - SEC Filing

THOMSON REUTERS
·
Sep 02

TScan Therapeutics Inc - Expects to Incur About $4.1 Million in Employee-Related Costs, Consisting Primarily of Pay Continuation and Related Benefits

THOMSON REUTERS
·
Sep 02

TScan Therapeutics - Jason A. Amello, CFO, and Chrystal Louis, Cmo, Terminated Effective Sept 2, 2026 - SEC Filing

THOMSON REUTERS
·
Sep 02

TScan Therapeutics Inc - Expects That Substantially All of Reorg Charges Will Result in Future Cash Expenditures

THOMSON REUTERS
·
Sep 02

TScan Therapeutics Cuts Workforce 75% in Reorganization to Focus on in Vivo Solid Tumor Cell Therapy

Reuters
·
Sep 02

TScan Therapeutics - Pauses Enrollment in Phase 3 Alloha-2 Study of Tsc-101 Due to Insufficient Capital

THOMSON REUTERS
·
Sep 02

TScan Therapeutics - to Share Preclinical Data Q1 2027, File Ind Q3 2027, Initiate Phase 1 Q4 2027

THOMSON REUTERS
·
Sep 02

TScan Therapeutics - to Reduce Workforce by About 75% and Extend Cash Runway into Q4 2027

THOMSON REUTERS
·
Sep 02

TScan Therapeutics - Strategic Reorganization Expected to Produce Cost Savings of $55 Mln Through End of 2027

THOMSON REUTERS
·
Sep 02

TScan Therapeutics Announces Strategic Reorganization to Focus on in Vivo Cell Therapy for Solid Tumors

THOMSON REUTERS
·
Sep 02